Currently out of the existing stock ratings of Ed Arce, 390 are a BUY (84.05%), 69 are a HOLD (14.87%), 5 are a SELL (1.08%).

Ed Arce

Work Performance Price Targets & Ratings Chart

Analyst Ed Arce, currently employed at WESTPARK, carries an average stock price target met ratio of 37.77% that have a potential upside of 39.97% achieved within 215 days.

Ed Arce’s has documented 886 price targets and ratings displayed on 47 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on GNFT, Genfit at 18-Aug-2025.

Wall Street Analyst Ed Arce

Analyst best performing recommendations are on TERN (TERNS PHARMACEUTICALS).
The best stock recommendation documented was for AKRO (AKERO THERAPEUTICS) at 1/16/2025. The price target of $50 was fulfilled within 11 days with a profit of $25.99 (108.25%) receiving and performance score of 98.41.

Average potential price target upside

of $67.58 (52.25%) on MDGL (MADRIGAL PHARMACEUTICALS).
of $36.35 (145.27%) on MIRM (MIRUM PHARMACEUTICALS).
of $32.04 (65.51%) on ACXP (ACURX PHARMACEUTICALS LLC).

GNFT Genfit PRTK Paratek Pharmaceuticals AKBA Akebia Ther ALBO Albireo Pharma AUPH Aurinia Pharmaceuticals AXLA Axcella Health DRNA Dicerna Pharmaceuticals MIRM Mirum Pharmaceuticals PLRX Pliant Therapeutics AKRO Akero Therapeutics ETNB 89bio ETTX Entasis Therapeutics Holdings IVA Inventiva Sa TVTX Travere Therapeutics VERA Vera Therapeutics ICPT Intercept Pharmaceuticals UNCY Unicycive Therapeutics CDTX Cidara Therapeutics TERN Terns Pharmaceuticals ABUS Arbutus Biopharma Corp ACXP Acurx Pharmaceuticals LLC ARCT Arcturus Therapeutics Holdings ASMB Assembly Biosciences CBAY Cymabay Therapeu DRRX Durect GALT Galectin Therapeutics KDNY Chinook Therapeutics ACRX AcelRx Pharmaceuticals ARDX Ardelyx ENTA Enanta Pharmaceuticals MDGL Madrigal Pharmaceuticals RARE Ultragenyx SYBX Synlogic AKAO Achaogen CNAT Conatus Pharmaceuticals ITRM Iterum Therapeutics PLC MLNT Melinta Therapeutics NBRV Nabriva Therapeutics AG TTPH Tetraphase Pharmaceuticals TRVN Trevena GLMD Galmed Pharmaceuticals Ltd ALGS Aligos Therapeutics NAMS NewAmsterdam Pharma Company N.V. Ordinary Shares SGMT Sagimet Biosciences Series A Common Stock COLL Collegium Pharmaceutical GEMP Gemphire Therapeutics NRBO Neurobo Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Ed Arce (HCWAINWRIGHT)

Buy

$4.92 (120.59%)

$13

1 months 20 days ago
(18-Aug-2025)

0/17 (0%)

$4.52 (100.89%)

Please subscribe to see the analyst performance score

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Ed Arce is most bullish on?

Potential upside of $5.36 has been obtained for TVTX (TRAVERE THERAPEUTICS)

Which stock is Ed Arce is most reserved on?

Potential downside of $4.92 has been obtained for GNFT (GENFIT)

What Year was the first public recommendation made by Ed Arce?

On 2015